Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
It is the first autotaxin inhibitor to be investigated in cancer patients
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Our collaboration with MediSage to present 'Current Approaches to Uro-Oncology' embodies a crucial stride towards comprehensive cancer care
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
Subscribe To Our Newsletter & Stay Updated
